What SURMOUNT-4 Trial Participants Say About Their Experience Taking Tirzepatide for Weight Loss

Qualitative study using semi-structured online exit interviews with 86 adults from 16 US-based SURMOUNT-4 clinical trial sites. Interviews covered experiences with receiving tirzepatide, using the injection pen device, and overall trial experience. Audio recordings were transcribed and analyzed using content analysis methodology. Participants were recruited after completing their participation in the SURMOUNT-4 randomized withdrawal trial.

Clinical trials typically report numbers — weight lost, side effects, lab values. This study captures what those numbers mean to real people. Understanding patient experience is crucial because even effective medications fail if people won't take them. The finding that participants valued tirzepatide's benefits enough to tolerate side effects and wanted to continue treatment provides real-world insight that complements the clinical data and helps set expectations for patients starting the medication.

As GLP-1/GIP receptor agonists like tirzepatide become mainstream weight management treatments, understanding patient experience becomes increasingly important for healthcare systems, prescribers, and the millions of potential patients. This qualitative data from SURMOUNT-4 adds a human dimension to one of the landmark obesity trials and helps inform realistic expectations about living with these medications long-term.

Selection bias is a significant concern — participants who had more positive experiences were likely more inclined to participate in exit interviews. The study population was 83% female and entirely US-based, limiting generalizability. All participants had been in the open-label phase first, so they knew they were receiving active drug. The qualitative methodology cannot quantify the magnitude of benefits or systematically compare to placebo experiences.